Clinically Relevant Molecular Subtypes in Leiomyosarcoma
the Cancer Therapy Advisor take:
Confirmed molecular subtypes in leiomyosarcoma are linked to distinct clinical outcomes, according to an article published online in the journal Clinical Cancer Research.
The authors used three previously identified molecular subtypes in leiomyosarcoma and aimed to determine whether their presence could be confirmed in independent cohorts.
In this study, 99 cases of leiomyosarcoma were profiled using 3’end RNA-Sequencing (3SEQ), but only 82 from The Cancer Genome Atlas (TCGA) were used to identify and confirm the existence of the three molecular subtypes.
Investigators identified two new formalin-fixed, paraffin-embedded tissue-compatible diagnostic immunohistochemical markers: LMOD1 for the first subtype and ARL4C for the second subtype.
Using a leiomyosarcoma tissue microarray sample with known clinical outcome, it was determined that subtype I was associated with a positive outcome in extrauterine leiomyosarcoma and that subtype II was related to a negative outcome in both uterine and extrauterine leiomyosarcoma.
The different molecular subtypes in leiomyosarcoma showed significant variations in gene expression levels, which suggest that they may respond differentially to the novel targeted therapies being developed.
Confirmed molecular subtypes in leiomyosarcoma are linked to distinct clinical outcomes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed